SCHEMBL5653932

SCHEMBL5653932

CCNC(=O)Nc1sc2c(ccc(=O)n2-c2ccccc2)c1-c1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 2/20 0.38
RAB9A P51151 2/20 0.36
GSK3B P49841 2/20 0.36
HTT P42858 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
GNRHR P30968 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
NPC1 O15118 1/20 0.36
GAA P10253 1/20 0.35
ALDH1A1 P00352 2/20 0.35
LMNA P02545 2/20 0.35
MAPT P10636 1/20 0.35
GSK3A P49840 1/20 0.35
JUN P05412 1/20 0.34
POLB P06746 1/20 0.34
RECQL P46063 1/20 0.34
TACR1 P25103 1/20 0.34
ACACB O00763 2/20 0.33
ACACA Q13085 2/20 0.33
KDM4E B2RXH2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5653218 0.88 CHEK1 (0.36) ABL1ALDH1A1LMNAMAPTTACR1
SCHEMBL5652117 0.85 CYP1A2 (0.41) SMN1; SMN2GAAALDH1A1LMNAMAPT
SCHEMBL5650652 0.85 ADORA3 (0.38) RAB9AHTTSMN1; SMN2NPC1GAA
SCHEMBL5648743 0.83 IKBKB (0.40) ALDH1A1LMNAMAPTKDM4E
SCHEMBL5649437 0.82 HPGD (0.44) RAB9AGSK3BSMN1; SMN2NPC1GAA
SCHEMBL5648185 0.76 MAT2A (0.38) GAAALDH1A1LMNAMAPTKDM4E
SCHEMBL5651227 0.74 ALDH1A1 (0.47) RAB9ASMN1; SMN2NPC1ALDH1A1LMNA
SCHEMBL5650705 0.74 KMT2A (0.43) RAB9AGSK3BL3MBTL1SMN1; SMN2ALDH1A1
SCHEMBL5652629 0.74 PLK1 (0.41) RAB9AHTTNPC1ALDH1A1LMNA
SCHEMBL5650136 0.73 MAPT (0.51) RAB9ASMN1; SMN2NPC1GAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7176215-B2 Bicyclic oxopyridine and oxopyrimidine derivatives CELLTECH R&D LIMITED (GB) 2007-02-13 US disclosed
US-20040254200-A1 Bicyclic oxopyridine and oxopyrimidine derivatives UCB PHARMA S.A. (BE) 2004-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254200-A1 Bicyclic oxopyridine and oxopyrimidine derivatives MAPK1, ALK, NAT1 ABL1 107/4885RAB9A 3641/4885GSK3B 1058/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.